exp3174 has been researched along with haloperidol in 2 studies
Studies (exp3174) | Trials (exp3174) | Recent Studies (post-2010) (exp3174) | Studies (haloperidol) | Trials (haloperidol) | Recent Studies (post-2010) (haloperidol) |
---|---|---|---|---|---|
236 | 29 | 43 | 20,330 | 1,753 | 3,294 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benachour, N; Vanderheyden, PML | 1 |
Prusty, S; Sahu, PK; Singh, VK; Subudhi, BB | 1 |
1 review(s) available for exp3174 and haloperidol
Article | Year |
---|---|
Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
Topics: Angiotensin II Type 1 Receptor Blockers; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Kinetics; Ligands; Protein Binding; Receptor, Angiotensin, Type 1; Receptors, Cell Surface; Signal Transduction | 2017 |
1 other study(ies) available for exp3174 and haloperidol
Article | Year |
---|---|
Conjugation to Ascorbic Acid Enhances Brain Availability of Losartan Carboxylic Acid and Protects Against Parkinsonism in Rats.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Ascorbic Acid; Behavior, Animal; Biological Availability; Brain; Disease Models, Animal; Drug Evaluation, Preclinical; Haloperidol; Humans; Losartan; Male; Parkinsonian Disorders; Rats; Rats, Wistar; Renin-Angiotensin System | 2018 |